Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Jan-Feb;35(1):54-57.
doi: 10.4103/lungindia.lungindia_93_17.

The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease

Sarthak Tandon  1 , Munish Gairola  1 , Manoj Pal  1 , Archana Aggarwal  1 , Kanika Sharma  1 , Ahmad Masroor Karimi  1 , Avik Mandal  1 , Rajiv Goyal  2 , Ullas Batra  3 , Inderjit Kaur  1
Affiliations
Case Reports

The use of adaptive intensity-modulated radiotherapy in the treatment of small-cell carcinoma lung refractory to chemotherapy in a patient with preexisting interstitial lung disease

Sarthak Tandon et al. Lung India. 2018 Jan-Feb.

Abstract

This is a case report of a 60-year-old diabetic, hypertensive male with a good performance status and a history of bilateral interstitial lung disease with a left upper lobe lung mass diagnosed to be a Stage IIB mixed small-cell/squamous cell carcinoma which was refractory to carboplatin- and etoposide-based chemotherapy. The patient was then taken up for adaptive intensity-modulated radiotherapy with tighter margin under image guidance with a mid-treatment replanning done at 25#. Acute toxicities were assessed weekly and showed no Grade 3 or more reactions. Pulmonary function test showed no detrimental changes during or after radiation. Response assessment at 12 and 20 weeks showed a partial response with decrease in metabolic activity on serial scans.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
(a) Phase I contouring showing planning target volume 1 and planning target volume 2 with fluorodeoxyglucose-positron emission tomography co-registration. (b) Phase II contouring with planning target volume n
Figure 2
Figure 2
(a) Dose-color wash denoting Phase I and Phase II, respectively. (b) Dose-volume histogram showing Phase I planning target volume 1 and planning target volume 2. (c) Dose-volume histogram showing Phase II planning target volume n
Figure 3
Figure 3
(a) Response evaluation with fluorodeoxyglucose-positron emission tomography at 12 weeks of completion of radiotherapy. (b) Response evaluation with fluorodeoxyglucose-positron emission tomography at 20 weeks of completion of radiotherapy
See this image and copyright information in PMC

References

    1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44. - PubMed
    1. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327:1618–24. - PubMed
    1. Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: A randomized study. J Clin Oncol. 1999;17:2092–9. - PubMed
    1. Yamaguchi S, Ohguri T, Matsuki Y, Yahara K, Oki H, Imada H, et al. Radiotherapy for thoracic tumors: Association between subclinical interstitial lung disease and fatal radiation pneumonitis. Int J Clin Oncol. 2015;20:45–52. - PubMed
    1. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, et al. Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol. 2015;10:116–25. - PubMed

Publication types